• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Results from the ISARIC Study: Clinical Features of First Wave COVID-19 Patients Hospitalized in the UK

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Docherty et al. (BMJ, 2020) studied the first wave of hospitalized COVID-19 patients in the UK to determine the following
    • Clinical features of this group
    • Risk factors associated with in-hospital mortality

METHODS:

  • Prospective observational cohort study (February 6 to April 19, 2020)
  • UK maintains a “prepandemic suite of protocols, documents, and agreements in preparation for future outbreaks”
    • The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study was part of the above suite of protocols
  • Setting
    • 208 acute care hospitals in England, Wales, and Scotland
  • Participants
    • Hospitalized COVID-19 patients
  • Study design
    • Clinical data were collected using a case report form developed by ISARIC and WHO
    • Minimum follow-up: 2 weeks
  • Primary outcomes
    • Admission to critical care (high dependency or ICU)
    • Mortality in hospital

RESULTS:

  • Total of 20,133 patients
    • Median (IQR) age: 73 (58-82) years | 60% men
  • Onset of symptoms
    • Median duration of symptoms before admission: 4 days (IQR 1-8 days)
  • Most common comorbidities
    • Cardiac disease: 31%
    • Uncomplicated diabetes: 21%
    • Non-asthmatic chronic pulmonary disease: 18%
    • Chronic kidney disease: 16%
  • No major comorbidities: 23%
  • Endpoint outcomes
    • Discharged alive: 41%
    • Died: 26%
    • Still in hospital: 34%
  • Outcomes for patients in critical care
    • Overall admission: 17%
    • Discharged alive: 28%
    • Died: 32%
    • Still in hospital: 41%
  • Outcomes for patients receiving mechanical ventilation
    • Discharged alive: 17%
    • Died: 37%
    • Still in hospital: 46%
  • Higher in-hospital mortality associated with
    • Increasing age
    • Male sex
    • Comorbidities (e.g. chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity)

CONCLUSION:

  • The COVID-19 outcomes consistent with other large cohorts
  • Outcomes worse for
    • Pre-existing characteristics: Men (across all age groups) | Older patients | Patients with comorbidities
    • Clinical course: Patients admitted to critical care or requiring mechanical ventilation
  • The authors state that additional COVID-19 studies from ISARIC will continue to be published over time and in addition they make the point that

Studies such as this cannot be developed, approved, and opened from the start of a pandemic in time to inform case management and public health policy

Our study has shown the importance of forward planning and investment in preparedness studies 

Learn More – Primary Sources:

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

COVID-19 Guidance: Key Highlights for Healthcare Professionals
Characteristics and Outcomes for 5700 COVID-19 Patients Hospitalized in the New York City Area
What are the Strongest Predictors of COVID-19 Hospitalization and Critical Illness?
MMWR Reports on Initial US COVID-19 Experience: Demographics, Mortality and Outcomes 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site